IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: A single-blind phase I study

• Published in: Vaccine 2007-06, Vol.25 (24), p.4641-4650
• Main Authors: Brignone, Chrystelle, Grygar, Caroline, Marcu, Manon, Perrin, Gaëlle, Triebel, Frédéric
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic - adverse effects; Adolescent; Adult; Allergy and Immunology; Antibodies, Viral - blood; Antigens, CD - administration & dosage; Antigens, CD - adverse effects; Antigens, CD - immunology; Applied microbiology; Biological and medical sciences; Blood; CD4-Positive T-Lymphocytes - immunology; Cells, Cultured; Dendritic cells; Enzymes; Fundamental and applied biological sciences. Psychology; Hemagglutination Inhibition Tests; Humans; Immunogenicity; Influenza; Influenza Vaccines - immunology; Interferon-gamma - biosynthesis; Interleukin-2 - biosynthesis; Laboratories; LAG-3; Leukocytes, Mononuclear; Male; MHC class II; Microbiology; Proteins; Safety; Single-Blind Method; Slag; T-Lymphocyte Subsets - immunology; Tumor Necrosis Factor-alpha - biosynthesis; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2007.04.019

Abstract sLAG-3 (IMP321), a natural high affinity ligand for MHC class II, was tested for safety, tolerability and its ability to increase Th-1-type T cell responses to a commercial trivalent split influenza vaccine (Agrippal® ) in a phase I single-blinded, randomized, controlled clinical trial. Twenty healthy volunteers were first injected with increasing doses of IMP321 alone (safety for first-in-man use). Then 40 volunteers were recruited into 4 consecutive cohorts of 10 subjects, who were randomly assigned to receive the flu vaccine plus 3, 10, 30 or 100 μg IMP321 or the flu vaccine plus saline control. All vaccine formulations were found to be generally well tolerated with similar frequency and intensity of adverse reaction in groups receiving IMP321 as in controls. Post-vaccination humoral immune responses, as determined 29 and 57 days later by assay of hemagglutinin inhibition activity were similar for both IMP321 and control groups. In contrast, the addition of 10, 30 or 100 μg IMP321 to the flu vaccine resulted in higher levels of Th1-type (IFN-γ, TNF-α or IL-2) flu-specific CD4 T cells in PBMC recovered at D29 and D57 and tested in a short-term ex vivo restimulation assay (6-colour FACS analysis after intra-cellular staining of cytokines). In summary, IMP321 as an adjuvant to a model antigen (Agrippal® ) was well-tolerated and may enhance T cell response vaccine immunogenicity.